FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Petition Urges FDA to Create Pathway for Brain-Computer Interfaces

[ Price : $8.95]

A citizen petition urges FDA to establish a regulatory framework for implantable brain-computer interfaces designed to expand huma...

FDA May Go Months Without Senate-Confirmed Commissioner: Analysis

[ Price : $8.95]

An analysis by PharmaVoice says FDA could remain without a Senate-confirmed commissioner for months as political and procedural hu...

Diamantas Touts FDA Moves to Boost U.S. Jobs

[ Price : $8.95]

FDA acting commissioner Kyle Diamantas uses a Fox News editorial to tout agency steps he says are providing new jobs for American ...

FDA Selects Dexcom as First Participant in Digital Health Pilot with CMS

[ Price : $8.95]

FDA names Dexcom as the first participant in its new Technology-Enabled Meaningful Patient Outcomes for Digital Health Devices Pil...

FDA Plan Would Fundamentally Reshape Drug Ads

[ Price : $8.95]

Two Sheppard attorneys say an FDA proposal to require complete safety and risk information within the content of direct-to-consume...

FDA, Industry Have MDUFA 6 Agreement in Principle

[ Price : $8.95]

Attorney Jake Leys says MDUFA 6 reauthorization has moved from negotiations into writing the commitment letter that spells out all...

FDA Approves GSK's Jideytro for ROS1-Positive Lung Cancer

[ Price : $8.95]

FDA approves GSK's Jideytro (zidesamtinib) for certain adults with locally advanced or metastatic ROS1-positive non-small cell lun...

FDA Cites Sanofi Over Misleading Beyfortus Promotional Emails

[ Price : $8.95]

FDA sends an untitled letter to Sanofi Vaccines U.S., alleging that promotional emails for its respiratory syncytial virus prevent...

Novo Nordisk Sues Lilly Over GLP-1 Ads

[ Price : $8.95]

Novo Nordisk sues Lilly in New Jersey federal court over what the company says is a misleading national ad campaign that compares ...

CGMP Issues at Indias Shimoga Chemicals

[ Price : $8.95]

FDA warns Indias Shimoga Chemicals about CGMP deviations in its production of active pharmaceutical ingredients.